The American Journal of Managed Care

Short-Term Improvements Seen in Patients With nAMD Switching to Faricimab

Faricimab demonstrated short-term improvements in visual and anatomical outcomes for nAMD patients switching from other anti-VEGF therapies. The study showed reductions in central macular thickness, ...

Ollin Biosciences Announces Upcoming Presentations of OLN324 Data in Diabetic Macular Edema and Wet Age-Related Macular Degeneration at the American Society of Retina ...

Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced upcoming oral presentations featuring results from its ...
Yahoo Finance

The Lancet publishes studies showing Roche’s faricimab improved and maintained vision in two leading causes of vision loss, extending time between treatments up to four months

Two papers in The Lancet highlight one-year results from Roche's phase III trials evaluating faricimab in neovascular or "wet" age-related macular (nAMD) and diabetic macular edema (DME) Reductions in ...

Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets

Acquisition adds seven commercial products including VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), and MIPLYFFA® (arimoclomol), andmore than ...
The American Journal of Managed Care

Faricimab Brought Early Control of Some Symptoms in AMD

Faricimab showed better control of PED, SHRM, and HRF compared to aflibercept in treatment-naïve nAMD and PCV patients. Both faricimab and aflibercept improved BCVA and reduced CMT, but faricimab ...
Medscape

Faricimab Could Save Injections for Age-Related Macular Degeneration and Diabetic Macular Edema

Faricimab, an experimental drug, could reduce the number of injections needed to treat both age-related macular degeneration (AMD) and diabetic macular edema (DME), phase 3 trials suggest. Faricimab's ...
News Medical

Faricimab lacks proof of added benefit over comparator therapies for macular edema

Since July 2024, faricimab has also been approved in Europe for the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion. The German Institute for Quality and ...
Nasdaq

Genentech: Faricimab Meets Primary Endpoint In Two Phase III Studies For Diabetic Macular Edema

(RTTNews) - Genentech, the U.S. unit of Swiss drug maker Roche Group (RHHBY), announced Monday positive topline results from two studies evaluating its investigational bispecific antibody, faricimab, ...
Business Wire

FDA Accepts Application for Genentech’s Faricimab for the Treatment of Wet Age-Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the ...
National Institute for Health and Care Excellence

Faricimab for treating diabetic macular oedema

The appraisal committee considered evidence submitted by Roche, a review of this submission by the evidence review group (ERG), and responses from stakeholders. See the committee papers for full ...
Nasdaq

The Lancet publishes studies showing Roche’s faricimab improved and maintained vision in two leading causes of vision loss, extending time between treatments up to four months

Two papers in The Lancet highlight one-year results from Roche’s phase III trials evaluating faricimab in neovascular or “wet” age-related macular (nAMD) and diabetic macular edema (DME) Across four ...